Evidence map›Paper›PMID 41823542›Full record

ArticleOncology reports2026

Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways.

Ayaka Kunishima, Takatsune Shimizu, Tetsuya Takimoto, Atsunobu Sagara, Hiroyuki Nobusue, Hidetoshi Hasuwa, Shinya Hasegawa, Yuka Tamaoki, Hitomi Miyake, Yumi Fukuchi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ayaka Kunishima *Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.
Takatsune Shimizu *Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.
Tetsuya TakimotoDepartment of Data Science, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Aichi 470‑1192, Japan.
Atsunobu SagaraDepartment of Pharmacy, Japanese Red Cross Medical Center, Shibuya, Tokyo 150‑8935, Japan.
Hiroyuki NobusueDepartment of Gene Regulation, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Aichi 470‑1192, Japan.
Hidetoshi HasuwaDepartment of Collaborative Research Resources (Laboratory Animal Center), Keio University School of Medicine, Shinjuku, Tokyo 160‑8582, Japan.
Shinya HasegawaDepartment of Environmental Health Sciences, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.
Yuka TamaokiDepartment of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.
Hitomi MiyakeDepartment of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.
Yumi FukuchiDepartment of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.
Hideyuki SayaDepartment of Gene Regulation, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Aichi 470‑1192, Japan.
Akihiro MutoDepartment of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poor survival of patients with osteosarcoma means that novel therapeutic targets are needed. A previously developed osteosarcoma mouse model revealed that HIF‑1 target genes are upregulated under anchorage‑independent growth conditions. HIF‑1α is highly expressed at the hypoxic invasion front

Indexed as

Bone NeoplasmsHypoxia-Inducible Factor 1, alpha SubunitOsteosarcomaAnimalsCarcinogenesisCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticGlycolysisHumansMiceMice, Inbred C57BLSignal TransductionTOR Serine-Threonine KinasesHIF1A protein, humanHif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitTOR Serine-Threonine Kinaseshypoxia inducible factor‑1osteosarcomatumor heterogeneity

Identifiers

PMID41823542
PMCPMC13007490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.